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Editorial
New recommendations of the Brazilian Society of 
Rheumatology: a new strategy
It is with great satisfaction that I see the Sociedade Brasileira 
de Reumatologia (SBR, Brazilian Society of Rheumatology) Rec-
ommendations for the management and treatment of psori-
atic arthritis,1 ankylosing spondylitis2 and systemic sclerosis3 
published in this issue of the Revista Brasileira de Reumatolo-
gia (RBR, Brazilian Journal of Rheumatology). Consensus and 
guidelines on diagnosis and treatment in Rheumatology have 
been published for over two decades. During that period, the 
strategies for elaborating the texts that guide most rheuma-
tologists and clinicians in managing patients with several 
rheumatic disorders have evolved greatly. In the ‘Recommen-
dations’ published in this RBR issue, the SBR Committees on 
Spondyloarthritis and Systemic Sclerosis used strategies for 
the search and elaboration of the fi nal text from the Projeto Di-
retrizes da Associação Médica Brasileira (Brazilian Medical Asso-
ciation ‘Guideline Project’), which requires that all statements 
in the text have at least one specifi c reference, graded accord-
ing to its level of evidence. After the initial elaboration of the 
text according to pre-established rules and in the ‘question 
and answer’ format, some rounds of internet discussion were 
necessary to refi ne it, before approval by the SBR and Brazil-
ian Medical Association. Both societies showed an excellent 
partnership to elaborate the fi nal text that would suit the 
Brazilian reality, without reducing the strength of evidence 
of the recommendations. With that effi cient partnership, the 
strength of the recommendations, increasingly based on con-
sistent evidence, will also serve as an instrument to discuss 
the implantation of governmental strategies for the diagnosis 
and treatment of rheumatic diseases.
After the new classifi cation criteria for axial4 and pe-
ripheral5 spondyloarthritis (SpA) issued by the Assessment 
on SpondyloArthritis International Society (ASAS) group, 
and the proposition of new guidelines for its treatment,6,7 
an update of the consensus on the ankylosing spondylitis 
and psoriatic arthritis treatment, published in the RBR in 
2007,8 became indispensable. Regarding the Recommendations 
for the management and treatment of ankylosing spondylitis,2 
three initial questions on the importance of the following 
were included: classifi cation criteria for axial and peripheral 
SpA (Recommendation 1); magnetic resonance imaging on 
the early SpA diagnosis (Recommendation 2); and HLA-B27 
as a prognostic factor (Recommendation 3). The so-called 
conventional treatment discussed physical therapy (Recom-
mendation 4), corticosteroids (Recommendation 5), non-ste-
roidal anti-infl ammatory drugs (NSAIDs) (Recommendation 
6), and conventional baseline drugs, such as methotrexate 
(MTX) and sulfasalazine (SSZ) (Recommendation 7). The use 
of biologic drugs, which have revolutionized the AS treat-
ment, is approached in seven questions regarding the in-
hibitors of tumor necrosis factor (anti-TNF) as follows: their 
indication (Recommendation 8); their effi cacy (Recommen-
dation 9); their safety (Recommendation 10); progression 
of structural damage (Recommendation 11); extra-articular 
manifestations (Recommendation 12); medication switch-
ing (Recommendation 13); and medication duration (Recom-
mendation 14). In addition, one question approaches other 
biologic drugs (Recommendation 15).
Within the SpA spectrum, psoriatic arthritis (PA) has also 
been increasingly studied over the last two decades, and new 
classifi cation criteria9 have been proposed and treatment 
guidelines,10 updated. The current Recommendations for the 
management and treatment of psoriatic arthritis1 also represent 
an update of the previous 2007 Brazilian Consensus.8 The fi rst 
three questions approach the classifi cation criteria as follows: 
recommend the CASPAR criteria9 (Recommendation 1); em-
phasize the importance of cutaneous, articular and nail as-
sessment (Recommendation 2); and highlight the signifi cant 
number of comorbidities (Recommendation 3). The conven-
tional treatment assessment comprises questions about the 
use of the following drugs: corticosteroids (Recommendation 
4); NSAIDs (Recommendation 5); and conventional drugs, 
mainly MTX, cyclosporine, and lefl unomide (Recommenda-
tion 6). Seven questions approach the use of biologic agents, 
especially anti-TNF drugs, as follows: their indication (Rec-
ommendation 7); their effi cacy (Recommendation 8); their 
safety (Recommendation 9); progression of structural dam-
age (Recommendation 10); concomitant use of conventional 
drugs (Recommendation 11); medication switching (Recom-
mendation 12); and medication duration (Recommendation 
13). In addition, one question approaches other biologic drugs 
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(Recommendation 14) and the effi cacy of the drugs acting 
mainly on the skin over affected joints (Recommendation 15).
One of the most fascinating and complex rheumatologic 
diseases is the systemic sclerosis (SSc), whose treatment 
still has to be improved. With the advent of the modern con-
cepts of SSc sine scleroderma,11 early SSc,12 and very early 
SSc,13 and the establishment of organ-specifi c strategies 
already outlined in the fi rst Recommendations of Treat-
ment14 proposed by the EUSTAR (EULAR Scleroderma Trial 
and Research) group, one can foretell that early diagnosis 
is essential for therapeutic success. The fi rst three ques-
tions approach the diagnosis of SSc (Recommendation 1), 
the importance of nailfold capillaroscopy (Recommendation 
2), and specifi c autoantibodies (Recommendation 3) in the 
early diagnosis and follow-up of scleroderma patients. Re-
garding organ-specifi c strategies, there are questions about 
antifi brotic drugs (Recommendation 4) and the treatment of 
calcinosis (Recommendation 5). Regarding vascular impair-
ment, there are questions about the treatment of Raynaud’s 
phenomenon (Recommendation 6) and of ischemic ulcers 
(Recommendation 7), and about the prevention of recurrent 
ischemic ulcers (Recommendation 8). The most frequent 
visceral impairment (digestive tract) is also approached on 
three questions about digestive tract hypomotility (Recom-
mendation 9), gastroesophageal refl ux (Recommendation 
10), and malabsorption syndrome (Recommendation 11). 
The impairment of vital organs is approached in specifi c 
questions about interstitial lung disease (Recommendation 
12), pulmonary arterial hypertension (Recommendation 13), 
scleroderma renal crisis (Recommendation 14), and cardiac 
involvement (Recommendation 15).
In conclusion, the new strategy of producing recommen-
dations for the diagnosis and treatment of the major rheu-
matic diseases, according to the modern rules of the Bra-
zilian Medical Association ‘Guideline Project’, represents a 
signifi cant gain in the strength of the SBR recommendations.
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